LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

Stopped The trial was terminated due to an out-licensing agreement after the new sponsor did not wish to continue the trial

Conditions

• Complicated Urinary Tract Infections

Interventions

• DRUG: LYS228
• DRUG: Standard of care therapy

Sponsor

Novartis Pharmaceuticals